The approach to treating asthma continues to evolve. Rescue bronchodilator therapies are giving way, both in medical practice and in the market, to prophylactic strategies, which include inhaled corticosteroids, long-acting beta2 agonists, and leukotriene antagonists.
Sales of combination therapies, leukotriene antagonists, and the introduction of more expensive novel agents are expected to breathe new life into the market.
The asthma market has undergone a significant revision over the past five years, with a host of therapeutic options becoming available and more being investigated worldwide. The need for innovative treatments is evident. As a chronic and multifaceted inflammatory disorder, asthma causes significant morbidity in affected individuals, including permanent structural damage to the airways and long-term reductions in lung function, according to Decision Resources.
Despite a greater number of good treatments coming to the market, there are still unmet needs. In its March 2004 report on the asthma market, Decision Resources identifies those needs as being safe and effective prophylactic therapies, convenient treatments that improve patient compliance, agents for refractory severe persistent asthma, improved diagnostic tests, and physician education and adherence to treatment guidelines…
An Asthma Breakdown
Asthma Therapies 2001-2012 Market Share
Sound Bites from the Field
Children and Asthma
Experts on this Topic
Alek Bituin. Senior Consultant, Navigant Consulting Inc., San Mateo, Calif.; Navigant Consulting is an independent consulting firm providing litigation, financial, healthcare, energy, and operational consulting services. For more information, visit navigantconsulting.com.
Rose Higgins. Senior VP, Head of Sales and Marketing, iMetrikus Inc., Carlsbad, Calif.; iMetrikus specializes in providing Web-based health management and remote monitoring systems. For more information, visit imetrikus.com.
Dennis Kane. VP, U.S. Sales and Marketing, Pharmacia Diagnostics, Kalamazoo, Mich.; Pharmacia Diagnostics is a leader in in vitro IgE diagnostic R&D. For more information, visit us.diagnostics.com.
Tom Luginbill. Senior Practice Executive, Brand Management Practice, Campbell Alliance, Raleigh, N.C.; Campbell Alliance is a specialized management consulting firm serving the pharmaceutical and biotechnology industries. For more information, visit campbellalliance.com.
Cynthia Mundy, Ph.D. Analyst, Decision Resources Inc., Waltham, Mass.; Decision Resources is a leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. For more information, visit decisionresources.com.
Alek Safarian. CEO, Novotech Pty Ltd., Sydney, Australia; Novotech is a leading CRO providing a comprehensive range of drug-development services to the pharmaceutical and biotechnology industries. For more information, visit novotech-cro.com.
Lawrence Sher, M.D., FAAP, FAAAI, FACAAI. Medical Director, Criterium Inc., Saratoga Springs, N.Y.; Criterium is a global technology-based contract research organization. For more information, visit criteriuminc.com.
Wade Sunada, Ph.D. Analyst, Navigant Consulting Inc., San Mateo, Calif.; Navigant Consulting is a specialized independent consulting firm providing litigation, financial, healthcare, energy, and operational consulting services. For more information, visit navigantconsulting.com.